Family Planning Associates Medical Group INC
Family Planning Associates Medical Group INC was paid $10.33M by Medicaid between Jan 2018 and Dec 2024, across 46 billing codes. Its largest line is J7307, Etonogestrel (contraceptive) implant system, including implant and supplies — 25% of everything it billed.
DOWNEY, CA 90241
Next to other Obstetrics & Gynecology Physician providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,663 | $3.34M | |
| 2019 | 19,833 | $1.87M | |
| 2020 | 8,663 | $575K | |
| 2021 | 11,255 | $923K | |
| 2022 | 12,939 | $1.18M | |
| 2023 | 16,630 | $1.47M | |
| 2024incomplete | 13,164 | $971K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 25% | 2,294 | 2,068 | $2.60M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 13% | 20,759 | 18,822 | $1.34M |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 11% | 1,371 | 1,061 | $1.11M |
| J3490 | Unclassified drugs | 9.7% | 18,961 | 16,454 | $1.01M |
| S0199 | Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs | 7.3% | 2,411 | 2,338 | $757K |
| S4993 | Contraceptive pills for birth control | 4.8% | 3,576 | 3,562 | $491K |
| A4267 | Contraceptive supply, condom, male, each | 3.8% | 19,776 | 19,629 | $388K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.6% | 3,201 | 2,964 | $370K |
| 58300 | 3.3% | 3,877 | 1,968 | $346K | |
| 11981 | 3.3% | 1,608 | 1,604 | $341K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.7% | 4,003 | 3,944 | $180K |
| 90651 | 1.6% | 795 | 790 | $166K |
34 more codes
| J7300 | Intrauterine copper contraceptive (paragard) | 1.6% | 228 | $161K |
| J7296 | Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg | 1.3% | 161 | $136K |
| 11976 | 1.2% | 2,248 | $119K | |
| 59840 | 1.1% | 715 | $111K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 1.0% | 1,743 | $104K |
| G9920 | Screening performed and negative | <1% | 2,820 | $76K |
| 58301 | <1% | 2,299 | $74K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 2,595 | $68K |
| S0190 | Mifepristone, oral, 200 mg | <1% | 1,525 | $61K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,167 | $59K |
| 99000 | <1% | 5,080 | $41K | |
| 76830 | Ultrasound, transvaginal | <1% | 482 | $30K |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 2,304 | $29K |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 1,650 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 732 | $23K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 732 | $19K |
| 99201 | <1% | 182 | $16K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 95 | $15K |
| J7301 | Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg | <1% | 22 | $14K |
| 01966 | <1% | 381 | $14K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 260 | $13K |
| 57454 | <1% | 140 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 238 | $7K |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 1,062 | $4K |
| 86592 | <1% | 751 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 73 | $3K |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 251 | $3K |
| 83986 | <1% | 340 | $1K | |
| 57061 | <1% | 28 | $951.76 | |
| 87481 | <1% | 24 | $792.23 | |
| 87799 | <1% | 24 | $723.52 | |
| 85018 | <1% | 95 | $637.83 | |
| 81025 | <1% | 56 | $198.02 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $40.46 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.